Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Thymalin is a thymus-derived peptide bioregulator with a unique dual identity in the Khavinson research tradition: the original Thymalin preparation is a polypeptide complex isolated from bovine thymus tissue (similar in concept to Cerebrolysin's complex peptide mixture origin), while the synthetic active fragment has been identified as the dipeptide L-glutamyl-L-tryptophan (Glu-Trp). Both forms are sometimes called "Thymalin" in the literature, though they represent fundamentally different compounds.
Thymalin was developed in the 1970s-1980s by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, making it one of the foundational and longest-clinically-used Khavinson bioregulator peptides. The compound has been used in Russian clinical practice for over 40 years for immune restoration, particularly in elderly populations.
Thymalin is the natural companion to Epitalon (already in the library): both are Khavinson peptide bioregulators from the same St. Petersburg Institute, with Thymalin targeting the thymus and Epitalon targeting the pineal gland. Together they form the foundation of the Khavinson approach to anti-aging through tissue-specific peptide bioregulators.
Thymalin's defining clinical claim, supported by the famous 266-person, 6-8 year longitudinal observation study (Khavinson and Morozov 2003), is that combined Thymalin + Epitalon treatment in elderly individuals reduced mortality by 2.5-fold compared to controls, with annual combined treatment over six years producing a 4.1-fold mortality reduction. These are substantial claims that have not been independently replicated in Western controlled trials.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Thymalin polypeptide complex (original) | Variable (mixture of components) |
| Synthetic Glu-Trp dipeptide | Short (minutes to ~1 hour) |
| Intramuscular Thymalin | Standard Russian clinical route |
| Subcutaneous Thymalin | Comparable to IM |
| Oral Thymalin | Limited bioavailability |
What it does
Main effects
- Immune restoration: Primary Russian-approved indication; 40+ years of clinical use in immunosuppressed patients, geriatric populations, and post-operative recovery PMID: 14523363
- T-cell function improvement: Improved T-cell numbers, CD4/CD8 ratios, and T-cell responses to mitogens in aged individuals
- NK cell activity enhancement: Improved NK cell cytotoxic function and antitumor immune surveillance
- Reduction in respiratory infections: 2.4-fold reduction in respiratory infections in elderly patients (Phase 2/3 immune restoration data)
- Mortality reduction (266-patient study): 2.0-2.1-fold reduction in annual mortality with Thymalin alone; 2.5-fold with combined Thymalin + Epithalamin; 4.1-fold with annual combined treatment over 6 years PMID: 14523363
- Thymic function restoration: Proposed to restore thymic-equivalent function in aged individuals with involuted thymus
- Post-operative immune recovery: Multiple Russian clinical studies in post-surgical immune restoration and reduced infection rates
- Anti-aging via direct DNA interaction: Proposed mechanism: Glu-Trp dipeptide binds specific gene promoter regions and modulates transcription of thymic-specific genes, restoring youthful gene expression in aged thymic tissue
What to watch for
Common side effects
- Generally well-tolerated: No major adverse events documented across decades of Russian clinical use in elderly and immunocompromised populations
- Mild injection site reactions: Mild, uncommon
- Mild fever: Occasional (immune activation)
- Theoretical prion disease risk (polypeptide complex form only): Bovine source; manufacturing controls address this; does not apply to synthetic Glu-Trp dipeptide
- Theoretical autoimmune triggering: Not documented as clinical issue; caution in known autoimmune disease
- Methodological limitations of safety tracking: 40+ years of Russian clinical use without major safety signals, but safety data gathered under different methodological standards than Western RCTs
- Quality concerns (research chemical Glu-Trp): Variable quality through unregulated sources; identity, concentration, sterility unverified
- NOT FDA-approved; NOT on FDA 503A bulk substance list: There is no lawful US supply route, including through compounding pharmacies
Key facts
Key facts worth knowing
- Thymalin exists in two distinct forms: the original polypeptide complex (bovine thymus tissue extract; the form used in Russian clinical practice and most clinical studies including the 266-patient mortality study; analogous to Cerebrolysin's mixture concept) and the synthetic dipeptide Glu-Trp (L-glutamyl-L-tryptophan; the identified minimum active sequence; used in modern research and non-medical contexts). The distinction between these forms matters significantly for evidence interpretation.
- Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in the 1970s-1980s. Thymalin was one of the first Khavinson bioregulators developed and helped establish the peptide bioregulator research paradigm. Khavinson has been nominated for the Nobel Prize in Medicine (2010) for peptide research and aging science, and has 6 peptide-based pharmaceuticals registered and approved for clinical use in Russia.
- The Khavinson 266-patient study (Khavinson VK, Morozov VG 2003): 266 elderly persons (60-80 years); 6-8 year observation period; bioregulators applied first 2-3 years; Thymalin alone: 2.0-2.1-fold annual mortality reduction; combined Thymalin + Epithalamin: 2.5-fold mortality reduction; annual combined treatment over 6 years: 4.1-fold mortality reduction. Also: normalized cardiovascular function, normalized endocrine function, improved immune indices, improved nervous system function, improved homeostasis and metabolism. Methodological limitations: NOT randomized, NOT blinded, NOT placebo-controlled; observational/longitudinal design. PMID: 14523363
- Russian regulatory approval since 1980s era. Approved for clinical use in Russia for: immune restoration in immunosuppressed patients; post-operative recovery; chronic infection management; geriatric immune support; adjunct in various conditions. 40+ years of Russian clinical use, among the longest continuously-used immune peptides globally.
- The Khavinson framework treats these peptides as episodic rather than continuous, as it does with Epitalon. The rationale is tissue-specific reprogramming, with effects proposed to persist after exposure ends, rather than continuous receptor activation that depends on the compound remaining present.
- Proposed mechanism, direct DNA interaction: Tissue-specific peptide bioregulators proposed to bind specific DNA sequences. Glu-Trp dipeptide demonstrated to bind specific gene promoter regions. Modulates transcription of thymic-specific genes. Restores youthful gene expression in aged thymic tissue. Mechanism distinctively different from Western pharmaceutical paradigms. Limited replication outside Khavinson laboratory.
- The Cytomax / Cytogen distinction in Khavinson framework: Cytomaxes are polypeptide complexes from tissue extracts (Thymalin, Cortexin, Epithalamin); effects persist 6-12 months after single course. Cytogens are synthetic counterparts (e.g., Glu-Trp for Thymalin) with shorter aftereffect than Cytomaxes. This distinction is important for understanding which "Thymalin" is being discussed.
- NOT FDA-approved. NOT on FDA's Section 503A bulk drug substances list, so it is not lawfully available through US compounding pharmacies. WADA status: Not specifically prohibited as of current information (verify before use in tested sport).
- Comparison with Thymosin Alpha-1 matters: Thymosin Alpha-1 (Zadaxin) has Phase 3 RCT data in 11,000+ patients across oncology, infectious disease, and immunodeficiency indications, 35+ country regulatory approval, and well-characterized pharmacology, vs Thymalin's Russian observational data primarily. Thymosin Alpha-1's immune effects are therefore substantially better validated.
Legal status
Legal status
Approved in Russia for immune restoration and various indications (40+ years). No FDA approval. NOT on FDA Section 503A bulk drug substances list, so it is not lawfully available through US compounding pharmacies. There is no lawful US supply route. Not WADA prohibited (verify current status before use in tested sport).